PreDiCT-TB members help commence the new PanACEA programme

March 14, 2017
No Comments

On the 7th and 8th of March the PanACEA held its inaugural meeting in Cape Town, South Africa, attended by a number of the PreDiCT-TB team including Gerry, Wilber, Derek and Stephen.  The meeting was the start of the new PanACEA programme that has built upon the work of the first PanACEA group.  PanACEA ( is trying to improve tuberculosis treatment.  It brings together five European and 14 African research groups all focused on the same goal bring new traetments to those who need them and optimizing the treatments we already have.

Stephen reports, “It was a great opportunity to rehearse the plans for the next five years of exciting research funded by the EDCTP who were represented by Monique Rijks-Surette.  The team discussed the innovative trials planned that include optimising the dose of rifampicin and performing early phase clinical studies on two novel anti-tuberculosis agents.  The results of earlier pharmacokinetic and molecular bacterial load studies were presented together with plans for the future.”

Mathematical modelling of data, which draws on our ongoing research in PreDiCT-TB will be incorporated into all aspect of the workplan. Capacity Development will be central to everything that PanACEA does and we look forward to using the best science to provide new cures for tuberculosis.

In addition to Stephen Gillespie (left), Nilesh Bhatt from National Public Health Institute Maputo Mozambique and Wilber Sabiiti from St Andrews are pictured below.

Consortium Partners

PreDiCT-TB brings together twenty-one leading European research partners in tuberculosis from both Industry and Academia

View More

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

The communication contained within this site reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained therein.